New combo therapy offers hope for hard-to-treat lymphoma patients
NCT ID NCT07264894
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of four drugs (zuberitamab, selinexor, dexamethasone, and thalidomide) in 30 adults with mantle cell lymphoma that came back or didn't respond to BTK inhibitors. The goal is to improve remission rates and keep the cancer under control longer. Participants first get 6 cycles of the combo, then a maintenance phase with two drugs to reduce relapse risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The first affiliated hospital of Zhengzhou University
Zhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a chemo-free cocktail tame mantle cell lymphoma?
- Engineered immune cells take on tough lymphomas
- New drug duo aims to outsmart resistant lymphoma
- New combo pill attack aims to control blood cancers
- New CAR-T therapy aims to stop High-Risk lymphoma early
- New drug takes aim at Hard-to-Treat blood cancers